title: An open-label phase I dose-finding study of APR-246 in hematological malignancies.
authors.affiliation: Karolinska University Hospital, Center of Hematology and Karolinska Institutet, Institution of Medicine, Huddinge, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Deneberg
authors.affiliation: Department of Medical Sciences, Uppsala University and Uppsala Academic Hospital, Uppsala, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Cherif
authors.affiliation: Department of Hematology, Skane University Hospital, Lund, Sweden.
authors.forename: V
authors.initials: V
authors.lastname: Lazarevic
authors.affiliation: Section of Hematology, South Älvsborg Hospital, Borås and Sahlgrenska Academy, Gothenburg, Sweden.
authors.forename: P-O
authors.initials: PO
authors.lastname: Andersson
authors.affiliation: Aprea AB, Solna, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: von Euler
authors.affiliation: Department of Hematology, Skane University Hospital, Lund, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Juliusson
authors.affiliation: Karolinska University Hospital, Center of Hematology and Karolinska Institutet, Institution of Medicine, Huddinge, Sweden.|Department of Medical Sciences, Uppsala University and Uppsala Academic Hospital, Uppsala, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Lehmann
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D011812:Quinuclidines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011812:Quinuclidines; C533410:eprenetapopt